首页 | 本学科首页   官方微博 | 高级检索  
     

构建叶酸修饰的乳腺癌靶向纳米超声造影微粒
引用本文:陈园园,徐 枫,杨 辉,刘 婷,周建桥,蔡晨蕾,叶园园,刘培峰,韩宝三. 构建叶酸修饰的乳腺癌靶向纳米超声造影微粒[J]. 中国组织工程研究, 2016, 20(30): 4425-4433. DOI: 10.3969/j.issn.2095-4344.2016.30.003
作者姓名:陈园园  徐 枫  杨 辉  刘 婷  周建桥  蔡晨蕾  叶园园  刘培峰  韩宝三
作者单位:上海交通大学医学院附属新华医院普外科、普外科实验室,上海市 200092;教育部高分子合成与功能构造重点实验室,浙江大学高分子科学与工程学系,浙江省杭州市 310027;上海交通大学医学院附属瑞金医院超声科,上海市 200025;上海交通大学医学院附属仁济医院中心实验室,上海市 200127
基金项目:国家自然科学基金(81172078),宁波市社会发展重大择优科技攻关项目(2012C5013)
摘    要:

关 键 词:生物材料  纳米材料  纳米粒  聚乙二醇  聚乳酸-羟基乙酸共聚物  叶酸受体  超声诊断  靶向对比剂  乳腺癌  国家自然科学基金  

Construction of folate-modified nanoparticles as ultrasound contrast agent targeting breast cancer
Chen Yuan-yuan,Xu Feng,Yang Hui,Liu Ting,Zhou Jian-qiao,Cai Chen-lei,Ye Yuan-yuan,Liu Pei-feng,Han Bao-san. Construction of folate-modified nanoparticles as ultrasound contrast agent targeting breast cancer[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(30): 4425-4433. DOI: 10.3969/j.issn.2095-4344.2016.30.003
Authors:Chen Yuan-yuan  Xu Feng  Yang Hui  Liu Ting  Zhou Jian-qiao  Cai Chen-lei  Ye Yuan-yuan  Liu Pei-feng  Han Bao-san
Abstract:BACKGROUND: Studies have testified that nano-ultrasound contrast agents have a strong permeability, making it possible to image the targeted tissues outside blood vessels and overcome the limitation that micron contrast agents are only available for the blood pool imaging.OBJECTIVE: To construct the folate-modified nanoparticles targeting breast cancer as ultrasound contrast agents, as well as to observe their ability to specifically bind to cells and imaging effect in vitro.METHODS: Both contrast agents, pegylated lactic acid-glycolic acid copolymer wrapping liquid fluorocarbon formed nanoparticles (mPP/PFOB) and folate modified pegylated lactic acid-glycolic acid wrapping liquid fluorocarbon formed nanoparticles (mPPF/PFOB), were constructed by phacoemulsification-evaporation method. (1)Biocompatibility detection: HFF-1 and MCF-7 cells in the logarithmic phase were cultivated with various concentrations (0, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2 and 1 g/L) of mPP/PFOB or mPPF/PFOB for 24 hours respectively, and then the cell viability was measured. (2)Targeting ability detection in vitro: HFF-1 and MCF-7 cells in the logarithmic phase were divided into three groups. Cy5-labled mPP/PFOB and mPPF/PFOB were added into groups A and B, respectively; the cells in group C were pretreated with folate for 2 hours, and sequentially Cy5-labled mPPF/PFOB was added into group C. Fluorescence intensity was detected by flow cytometry after 0.5 hours of culture. The distribution of contrast agents in cells was observed using confocal microscopy after 20 minutes of culture. (3)Ultrasound imaging in vitro: there were three groups: saline was as group A; the suspension of saline and mPPF/PFOB nanoparticles was prepared as group B; MCF-7 cells were resuspended with the mixture of saline and mPPF/PFOB nanoparticles to prepare the suspension of nanoparticles and cells as group C. In each group, the suspension was added into latex gloves, that were then tightened and immersed in water. Finally, the ultrasound was use to detect the ultrasound imaging effect in vitro.RESULTS AND CONCLUSION: Neither nanoparticles were with significant cytotoxicity. The flow cytometry showed that the mean fluorescence intensity in MCF-7 cells of group B was significantly higher than that of groups A and C. But there were no significant differences in the mean fluorescence intensity in HFF-1 cells among the three groups. It was observed that mPPF/PFOB mainly gathered around the MCF-7 cell membrane, while mPP/PFOB randomly distributed in the cytoplasm. After mPPF/PFOB binding to MCF-7 cells, they could enhance ultrasound echo in vitro. These findings indicate that the targeted nanoparticles mPPF/PFOB have good biocompatibility and can specifically bind to breast cancer MCF-7 cells in vitro and enhance the imaging capability.
Keywords:Nanoparticles  Ultrasonography  Contrast Media  Tissue Engineering  
点击此处可从《中国组织工程研究》浏览原始摘要信息
点击此处可从《中国组织工程研究》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号